Largest study to date to characterize natural history of rare retinal diseasesRESEARCH TRIANGLE PARK, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE)…
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the…
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now…
Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and medicine and was presented…
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25…
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader…
Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight…
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of…
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the…
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to…